曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛的临床效果分析(1)
[摘要] 目的 观察曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛的临床效果。 方法 将60例不稳定型心绞痛患者按照随机数字表法分为观察组(常规治疗+曲美他嗪联合阿托伐他汀钙治疗)和对照组(常规治疗)，每组各30例。比较两组治疗后的疗效及两组患者治疗前后血脂各项指标的变化情况、心绞痛日均发作次数、每次心绞痛持续发作时间，并记录药物不良反应。 结果 观察组的总有效率明显高于对照组(95.0% vs 77.5%，P<0.05)。观察组治疗后的TC、TG、LDL-C、HDL-C水平较对照组变化更显著(t=3.521、2.643、3.138、2.327，P<0.05)，观察组治疗后的心绞痛发作次数以及发作持续时间较治疗前及对照组均显著降低(t=2.357、3.128，P<0.05)。 结论 曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛临床效果好，可降低血脂水平，还能减少心绞痛发作次数，减少心绞痛发作时间，安全性好，值得广泛推广和应用。
[关键词] 不稳定型心绞痛；曲美他嗪；阿托伐他汀钙
, 百拇医药
[中图分类号] R541.4 [文献标识码] B [文章编号] 1673-9701(2015)21-0030-03
[Abstract] Objective To observe the clinical effect of trimetazidine combined with atorvastatin calcium in the treatment of unstable angina pectoris. Methods A total of 60 cases of unstable angina pectoris patients were divided into the observation group (conventional therapy plus trimetazidine combined with atorvastatin calcium therapy) and control group (conventional treatment) according to random number table， 30 cases in each group. The efficacy of two groups after treatment and the changes of blood lipid indexes， angina attack frequency of angina pectoris， each daily average time continued to attack of the two groups before and after treatment were compared and recorded the adverse drug reaction. Results The total effective rate of observation group was significantly higher than that of the control group (95.0% vs 77.5%， P<0.05). The TC， TG， LDL-C， HDL-C levels of observation group after treatment changed more significantly than the control group (t=3.521， 2.643， 3.138， 2.327， P<0.05)， the angina attack frequency and duration of attack of the observation group after treatment were significantly decreased than before treatment and the control group (t=2.357， 3.128， P<0.05). Conclusion Trimetazidine combined with atorvastatin calcium in the treatment of unstable angina pectoris clinical effect is good， not only can decrease the level of blood lipid， but also can reduce the frequency of angina pectoris， reduce the attack of angina pectoris， good safety， and is worthy of popularization and application.
, 百拇医药
[Key words] Unstable angina pectoris； Trimetazidine； Atorvastatin calcium
不稳定型心绞痛(unstable angina pectoris，UAP)是一种介于稳定型心绞痛和典型急性心肌梗死(AMI)之间的临床症候群，具有起病急、进展快、病症严重、死亡率高等特点[1，2]。UAP的发病机制为不稳定斑块发生破裂，致使继发血栓形成，易发展为急性心肌梗死，严重时可危及患者的生命。UAP治疗目的在于改善心肌供血，提高心肌细胞对缺血的耐受性、预防血栓形成。国内外研究证实，他汀类降脂药物是目前治疗不稳定型心绞痛的有效方法之一，具有较好的稳定易损斑块的效果[3，4]。曲美他嗪是一种新型的抗心肌缺血药物，可显著改善机体缺氧缺血心肌细胞的能量代谢。本研究旨在观察曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛的临床效果，现报道如下。
1 资料与方法
1.1一般资料, 百拇医药(王力 邢娟)
[关键词] 不稳定型心绞痛；曲美他嗪；阿托伐他汀钙
, 百拇医药
[中图分类号] R541.4 [文献标识码] B [文章编号] 1673-9701(2015)21-0030-03
[Abstract] Objective To observe the clinical effect of trimetazidine combined with atorvastatin calcium in the treatment of unstable angina pectoris. Methods A total of 60 cases of unstable angina pectoris patients were divided into the observation group (conventional therapy plus trimetazidine combined with atorvastatin calcium therapy) and control group (conventional treatment) according to random number table， 30 cases in each group. The efficacy of two groups after treatment and the changes of blood lipid indexes， angina attack frequency of angina pectoris， each daily average time continued to attack of the two groups before and after treatment were compared and recorded the adverse drug reaction. Results The total effective rate of observation group was significantly higher than that of the control group (95.0% vs 77.5%， P<0.05). The TC， TG， LDL-C， HDL-C levels of observation group after treatment changed more significantly than the control group (t=3.521， 2.643， 3.138， 2.327， P<0.05)， the angina attack frequency and duration of attack of the observation group after treatment were significantly decreased than before treatment and the control group (t=2.357， 3.128， P<0.05). Conclusion Trimetazidine combined with atorvastatin calcium in the treatment of unstable angina pectoris clinical effect is good， not only can decrease the level of blood lipid， but also can reduce the frequency of angina pectoris， reduce the attack of angina pectoris， good safety， and is worthy of popularization and application.
, 百拇医药
[Key words] Unstable angina pectoris； Trimetazidine； Atorvastatin calcium
不稳定型心绞痛(unstable angina pectoris，UAP)是一种介于稳定型心绞痛和典型急性心肌梗死(AMI)之间的临床症候群，具有起病急、进展快、病症严重、死亡率高等特点[1，2]。UAP的发病机制为不稳定斑块发生破裂，致使继发血栓形成，易发展为急性心肌梗死，严重时可危及患者的生命。UAP治疗目的在于改善心肌供血，提高心肌细胞对缺血的耐受性、预防血栓形成。国内外研究证实，他汀类降脂药物是目前治疗不稳定型心绞痛的有效方法之一，具有较好的稳定易损斑块的效果[3，4]。曲美他嗪是一种新型的抗心肌缺血药物，可显著改善机体缺氧缺血心肌细胞的能量代谢。本研究旨在观察曲美他嗪联合阿托伐他汀钙治疗不稳定型心绞痛的临床效果，现报道如下。
1 资料与方法
1.1一般资料, 百拇医药(王力 邢娟)